Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy

M. Mahadeo, Kris; Khazal, Sajad; Abdel‐Azim, Hisham; C. Fitzgerald, Julie; Taraseviciute, Agne; M. Bollard, Catherine; Tewari, Priti; Duncan, Christine; Traube, Chani; McCall, David; E. Steiner, Marie; M. Cheifetz, Ira; Lehmann, Leslie; Mejía, Rodrigo; M. Slopis, John; Bajwa, Rajinder; Kebriaei, Partow; L. Martin, Paul; Moffet, Jerelyn; McArthur, Jennifer; Petropoulos, Demetrios; O’Hanlon Curry, Joan; Featherston, Sarah; Foglesong, Jessica; Shoberu, Basirat; Gulbis, Alison; E. Mireles, Maria; Hafemeister, Lisa; Nguyen, Cathy; Kapoor, Neena; Rezvani, Katayoun; S. Neelapu, Sattva; J. Shpall, Elizabeth; Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network, the

doi:10.1038/s41571-018-0075-2

Public

Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy

Published in Nature Reviews Clinical Oncology • Aug 6, 2018

Authors:

Kris M. Mahadeo

Sajad Khazal

Hisham Abdel‐Azim

Abstract

acute lymphoblastic leukaemia became the first gene therapy to be approved in the USA. This innovative form of cellular immunotherapy has been associated with remarkable response rates but is also associated with unique and often severe toxicities, which can lead to rapid cardiorespiratory and/or ne...

Subject

Chimeric antigen receptor

Medicine

Immunotherapy

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!